Viewing Study NCT05147493

Home

Certify Doc

Genes

Clinical Trials

CompTox

DrugMatrix

Open Targets

Products

Support

Bugs

Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug

Ignite Creation Date: 2025-12-25 @ 12:58 AM

Ignite Modification Date: 2025-12-25 @ 11:12 PM

Study NCT ID: NCT05147493

Status: UNKNOWN

Last Update Posted: 2022-03-29

First Post: 2021-11-05

Is NOT Gene Therapy: False

Has Adverse Events: False

Brief Title: A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment

Sponsor: Hellenic Society of Hematology

Organization:

Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module